By: Christopher Parrella, Esq., CPC, CHC, CPCO
Parrella Health Law, Boston, Ma.
A Health Care Provider Defense and Compliance Firm

The Drug Enforcement Administration (DEA) has announced the creation of a special registration process for healthcare providers to prescribe controlled substances, such as opioids and stimulants, via telemedicine. This initiative addresses a mandate from the 2008 Ryan Haight Act, which required the DEA to establish such a process to enhance patient access to necessary medications through telehealth services.

The proposed special registration system includes several stipulations:

• State Alignment: Providers must be physically located in the same state as their patients to prescribe Schedule II medications, including Ritalin and Adderall.
• In-Person Consultation Requirement: At least 50% of prescriptions must be issued following in-person appointments, potentially impacting telehealth-focused practices.

These proposed regulations have elicited concerns from telehealth advocates. The Alliance for Connected Care expressed apprehension, stating that mandating specific portions of patient care to be conducted in person and imposing geographic restrictions could undermine the benefits of virtual healthcare, particularly for patients in underserved areas.

The DEA’s action comes as the COVID-19 public health emergency, which temporarily relaxed certain telemedicine restrictions, is set to expire. During the pandemic, emergency measures allowed for increased flexibility in prescribing controlled substances via telehealth without prior in-person evaluations. The new proposal seeks to establish a permanent framework, but its future remains uncertain with the impending change in administration.

It’s important to note that the DEA has extended the current telemedicine flexibilities through December 31, 2025, allowing providers to continue prescribing controlled substances via telehealth without an in-person visit during this period.

As the situation evolves, healthcare providers and patients should stay informed about regulatory changes affecting telemedicine practices, especially concerning the prescription of controlled substances.

Take Action Now to Protect Your Telemedicine Practice

The DEA’s proposed special registration process for telemedicine prescribing of controlled substances introduces new restrictions that could significantly impact your practice and patient care. If your organization provides telehealth services, now is the time to assess how these changes may affect your ability to prescribe essential medications.

Parrella Health Law is here to help. We can assist with:

• Reviewing your telemedicine prescribing policies for compliance
• Advising on DEA registration requirements and best practices
• Advocating for regulatory changes that protect telehealth accessibility

Don’t wait until the rules are finalized—reach out today to ensure your practice is prepared. Contact Parrella Health Law at 857.328.0382 or email Chris directly at cparrella@parrellahealthlaw.com to discuss your next steps.